Optic Nerve

Prototype Solutions for Optic Nerve Injury

The overarching goal of this program is to provide biomanufacturing for an emerging area of medical technology and innovation to support standard procedures toward a device, biologic, or combination prototype to maintain, re-establish or regenerate damaged visual pathways.

The Awardee will develop an innovative solution to a critical problem in visual loss. Applications were expected to address one or more of the following focus areas in nerve regeneration or end-organ health:

  1. 1. Enhance optic nerve regeneration.
  2. 2. Re-establish neuronal connections between retinal ganglion cells and the lateral geniculate nucleus with high efficiency.

This effort aims to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; and translational studies to support the fluid transfer of knowledge from basic principles to clinical solutions.

The research project award recipient was selected from the Offerors who responded to MTEC’s Request for Project Proposals (18-02-OpticNerve).

Title of Project:  Preservation and Restoration of Vision in Optic Neuropathies: Porcine traumatic model for advancing neuroprotective and regenerative therapies towards human testing
Award Amount:  $3,000,000
Project Duration: 3 years
Project Team:  Byers Eye Institute at Stanford University (Prime); Boston Children’s Hospital (sub)
Project Objective:  The major goals of this project are to develop a large animal model of traumatic optic neuropathy, and to test for efficacy in this new model therapeutic combinations that successfully promote optic nerve regeneration in the rodent.

Year One Accomplishments:

  • Assembled a group of subject matter experts, at the vice president or director level, from the health and non-health sectors to establish industry best practices for enterprise-wide integrated supply chain design and execution.
  • Characterized, in comparison to industry best practice (IBP) organizations, Defense Health Agency (DHA) on attributes of a Fully Integrated Supply Chain Organization. To accomplish this we:
    • Carried out interviews with entities across the DHA and interviews with non-military supply chain organizations.
    • Provided recommendations to advance DHA to IBP level or beyond.
    • Vetted the characterization with key MEDLOG stakeholders as well as with 14 members of the Arizona State University Flag Officer Advisory council.
  • Presented Year 1 activity summary at the Interim Progress Review (IPR) meeting held at Ft. Detrick on 23-Apr-2019.
  • Developed Phase 1 report, which elaborated on the Characterization report and assessed technologies and processes for consideration by DHA as it evolves into an enterprise level military logistics and supply chain organization.
  • Collaborated with DHA to identify a set of six fundamental FISCO functions and appropriate support functions for inclusion in a roadmap to bridge the gap between current DHA practices and IBP.
  • Developed a special topic report on supply chain risk management with focus on medical product recalls.